Меню
Набор скоро начнётся NCT07349459

Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

Без фазы С лечением Melatonin Breast Cancer Patients Diagnosed Vitamin D Concentration Doxorubicin

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Group 1 (Doxorubicin group), Group 2: Vitamin D group, Group 3: melatonin group.
Кому может быть актуально
Состояния в реестре: Melatonin, Breast Cancer Patients Diagnosed, Vitamin D Concentration, Doxorubicin. Базовые параметры: 18 лет — 65 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Египет
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Clinical Study Evaluating Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

Обзор

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

Подробное описание

Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge.

Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase .

Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 .

To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades .

Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer .

Melatonin has emerged as a promising adjuvant that protects against doxorubicin-induced cytotoxicity, as highlighted by various studies and clinical trials that have demonstrated cardioprotective effects against several chemotherapeutic agents . Moreover, melatonin exhibits low toxicity and easily enters cells owing to its good solubility in both aqueous and organic phases and its highly lipophilic properties . Vitamin D plays an important role in the regulation of body function including the cardiovascular system .

Vitamin D deficiency results in the decrease of active calcitriol leading to inhibition of proliferation of cardiomyocytes and vascular smooth muscles .

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

Вмешательства

  • Препарат Group 1 (Doxorubicin group)
    30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.
  • Препарат Group 2: Vitamin D group
    patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks
  • Препарат Group 3: melatonin group
    patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks

Первичные конечные точки

  • Decreasing incidence and severity of cardiotoxicity [Срок оценки: 12 weeks]
Вторичные конечные точки (1)
  • change in the serum level of the (biological markers). [Срок оценки: 12 weeks]

Критерии участия

Критерии включения

  • Age from 18 to 65 years old.
  • Gender: female.
  • Positive breast cancer women who are scheduled to receive Doxorubicin.
  • Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.
  • Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.
  • Normal renal and liver function tests.

Критерии исключения

  • Pregnant or breastfeeding women.
  • Women with HER-2 positive of breast cancer.
  • Formerly treated with Doxorubicin.
  • Patients with a known hypersensitivity to any of the used drugs.
  • On other concomitant vitamins or food supplements.
  • Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
  • Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction < 50%.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Двойное слепое
Основная цель
Профилактика

Центры проведения

Египет · 1 центр
  • Tanta University — Tanta

Идентификаторы

NCT: NCT07349459 · 36265MD408/5/25

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗